| Name | Title | Contact Details |
|---|
Northern Michigan Regional Hospital is one of the leading companies in Healthcare, Pharmaceuticals, & Biotech industry. Northern Michigan Regional Hospital is based in Petoskey, MI. You can find more information on Northern Michigan Regional Hospital at www.northernhealth.org
Central Peninsula Hospital, Inc., an acute care hospital, provides patient and resident centered care services serving the Central Peninsula area. It offers emergency care, anesthesia, emergency medicine, family medicine, ENT, general surgery, internal medicine, neurology, OB/GYN, ophthalmology, orthopedics, pathology, pediatrics, podiatry, psychiatry, and radiology services; and behavioral health services that include depression screenings, substance abuse treatment, and substance abuse treatment services. The company also provides imaging services that include diagnostic imaging, digital mammography examinations, computer axial tomography procedures, ultrasound/sonography, nuclear medicine, and magnetic resonance imaging; physical, occupational, speech, and massage therapy services; outpatient weight loss, walking and exercise programs, cardiac rehabilitation, and diabetes management services; and diabetes education services. In addition, it offers family birth center services; laboratory services that include chemistry, hematology, transfusion medicine, serology, urinalysis, microbiology, and molecular biology testing; various treatments to outpatients include chemotherapy, blood transfusions, platelet transfusions, IV antibiotics, and hydration and electrolyte replacement; and sleep center services. Central Peninsula Hospital, Inc. was formerly known as Central Peninsula General Hospital, Inc. The company was founded in 1971 and is based in Soldotna, Alaska with practices in Kenai and Soldotna, Alaska.
The Association of State and Territorial Health Officials is a Arlington, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Orbus Therapeutics is dedicated to developing products that treat rare diseases for which there are few, if any, effective therapies. The company’s product candidate in development is eflornithine in an oral solution. Eflornithine is a novel cytostatic agent, which Orbus Therapeutics is developing for the treatment of patients with anaplastic glioma (AG), or Grade 3 glioma, a rare form of central nervous system cancer. Eflornithine irreversibly inhibits ornithine decarboxylase (ODC), a key enzyme in mammalian polyamine biosynthesis that is up-regulated in various types of cancer. Orbus Therapeutics intends to develop and commercialize eflornithine in North America.
Wellbeing Digital Sciences Inc. is an evidence-based mental healthcare company focused on the development and implementation of innovative clinical treatment solutions, including psychedelic medicine and digital therapeutics, as supported by clinical research. Its mission is supported by a network of North American clinics that provide forward-thinking therapies and other types of treatment to patients as well as through a contract research organization that offers clinical trials services to clients pursuing drug development.